Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
about
Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classificationThe incretin system and cardiometabolic diseaseBenefits of healthy adipose tissue in the treatment of diabetes.Glucagon-like peptide-1 and-2 levels in children with diabetic ketoacidosisAlogliptin: a new addition to the class of DPP-4 inhibitors.Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.New potential adjuncts to treatment of children with type 1 diabetes mellitus.Beta-cell protection and therapy for latent autoimmune diabetes in adults.Treatment of diabetes with glucagon-like peptide-1 gene therapy.Alogliptin benzoate for the treatment of type 2 diabetes.Adipose tissue, hormones, and treatment of type 1 diabetes.Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy.The latest pharmacotherapy options for type 1 diabetes.DPP-4 inhibitors: focus on safety.Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts.DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.The effect of oral and intravenous dextrose on C-peptide secretion in ponies.[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls.
P2860
Q33683839-705CA58E-E4D4-4180-A5FD-EBEFFB82BEB9Q33776092-7DFE3B4F-5DB0-4897-9EAD-244D2232F614Q34023537-7EC87C61-B36D-47E8-BB2E-14A6550CE48BQ34423035-4C17647D-D582-42CE-8F5A-8B8BEE4B206BQ34620671-5612650C-EB22-4F22-90FB-15AED47292E6Q37105326-0F28FAB9-CCFF-485D-8280-16DDB438C069Q37353820-08F0D957-2643-442F-AB82-CC9199DBE32CQ37624274-3F691DE7-15AC-4DD0-8570-06DD109CE9AAQ37804398-ACCCAC34-44FD-4651-BF46-461C1F1EF2A4Q37980541-7021A805-CD18-4141-BAD0-935A87832246Q38027744-162E9823-C14B-497D-B5FE-1249C514B91AQ38071010-8357610E-EF2C-41B7-A818-EB60C34004E4Q38167387-16B74498-B8E4-462E-A168-5769D3B28A8AQ38285608-68326801-096E-4C16-BE95-E18860E4D2ECQ42121004-E010E2F1-13B5-4B75-B371-93BC848F2CA1Q43253089-B4186376-E235-499F-8378-F3A5ABABEE3CQ46565923-D2969A42-B86E-4472-9E2D-F4577D65877DQ46625434-1E02E1D3-212A-454E-B617-E79550B0B580Q51319337-A8D00DE8-4349-4B00-8C02-F01C9BD798A3
P2860
Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Glycaemic effects of incretins ...... emphasis on studies in humans.
@ast
Glycaemic effects of incretins ...... emphasis on studies in humans.
@en
type
label
Glycaemic effects of incretins ...... emphasis on studies in humans.
@ast
Glycaemic effects of incretins ...... emphasis on studies in humans.
@en
prefLabel
Glycaemic effects of incretins ...... emphasis on studies in humans.
@ast
Glycaemic effects of incretins ...... emphasis on studies in humans.
@en
P1433
P1476
Glycaemic effects of incretins ...... emphasis on studies in humans.
@en
P2093
John Dupre
P304
P356
10.1016/J.REGPEP.2004.06.003
P577
2005-06-01T00:00:00Z